NEXTGEN BIOSCIENCE CO., LTD.

City:

Seongnam-si

Country:

South Korea

Published Applications:

Last publication date:

2026-04-30

Patent Grants:

Last grant date:

2024-11-19

Top Inventors for applications by NEXTGEN BIOSCIENCE CO., LTD.

These are the the leading inventors for applications assigned to NEXTGEN BIOSCIENCE CO., LTD.:

Eun Jeong KIM 3 Seongnam-si, South Korea
Bong-yong LEE 3 Seoul, South Korea
Yang Hae Park 2 Seoul, South Korea
Soo Sung Kang 1 Bucheon-si, South Korea

Yanghae PARK 1 Seoul, South Korea
Young Ah Shin 1 Seongnam-si, South Korea
Na Ra Han 1 Yongin-si, South Korea
Shin Ae Kim 1 Suwon-si, South Korea

Young Ah SHIN 1 Seongnam-si, Gyeonggi-do, South Korea
Hojung Choi 1 Incheon, South Korea
Su Jae YANG 1 Seoul, South Korea
Shin Ae KIM 1 Suwon-si, Gyeonggi-do, South Korea

Eun Jeong Kim 1 Seongnam-si, Gyeonggi-do, South Korea
Mi Ji LEE 1 Anyang-si, Gyeonggi-do, South Korea
Na Ra HAN 1 Yongin-si, Gyeonggi-do, South Korea
Minh Thanh LA 1 Seoul, South Korea

Eunjeong KIM 1 Seongnam-si, South Korea
Mi Ji Lee 1 Anyang-si, South Korea
Soo Sung KANG 1 Bucheon-si, Gyeonggi-do, South Korea
Bongyong LEE 1 Seoul, South Korea

Recent patent applications by NEXTGEN BIOSCIENCE CO., LTD.

NEXTGEN BIOSCIENCE CO., LTD. based in Seongnam-si, KR has been assigned the rights to these inventions. The list includes both Pending Applications and Patent Grants:

#1 | 2026-04-30

US20260116902A1

Chemistry; metallurgy

NOVEL COMPOUND AS FUNCTIONAL ANTAGONIST FOR S1PR1 AND S1PR4

#2 | 2024-08-22 ✅ Patent 12,145,929 granted on 2024-11-19

US20240279216A1

Chemistry; metallurgy

Piperidine derivative and pharmaceutical composition for inhibiting autotaxin comprising same

#3 | 2024-05-09 ✅ Patent 11,957,665 granted on 2024-04-16

US20240148698A1

Human necessities

PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING ALOPECIA AREATA ACTING AS A FUNCTIONAL ANTAGONIST FOR S1PR1 AND S1PR4

#4 | 2024-02-08 ✅ Patent 12,048,689 granted on 2024-07-30

US20240041836A1

Human necessities

Pharmaceutical composition for preventing or treating inflammatory bowel disease acting as a functional antagonist for S1PR1 and S1PR4

Also check out NEXTGEN BIOSCIENCE CO., LTD.'s (Seongnam-si, South Korea) applicant profile with 5 patent applications submitted.

AssigneeID:

346971 ⎘